Backstrom Jay T. - 08 Jul 2026 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Reporting relationship: Director
Issuer ticker: AGIO
Reported as of: 08 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jul 2026, 16:18:00 UTC
Prior SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ William Cook, as attorney-in-fact for Jay Backstrom

Key filing fact

Backstrom Jay T. filed Form 4 for AGIOS PHARMACEUTICALS, INC. (AGIO) on 10 Jul 2026.

Key facts

This page summarizes Backstrom Jay T.'s Form 4 filing for AGIOS PHARMACEUTICALS, INC. (AGIO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Jul 2026, 16:18.

Change

Previous filing in this sequence was filed on 23 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001796398 Primary reporting owner

Backstrom Jay T.

Relationship: Director
Address: C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE
Signature: /s/ William Cook, as attorney-in-fact for Jay Backstrom
Signature date: 10 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AGIO transaction

Common stock

Award

Transaction value
Shares: +1,447
Change %
Price: $0.000000^*
Shares after: 1,447
Date: 08 Jul 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AGIO transaction Derivative

Restricted stock units

Options Exercise

Transaction value
Shares: -1,447
Change %: -33%
Price: $0.000000^*
Shares after: 2,894
Date: 08 Jul 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 1,447
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

Footnote F2

The restricted stock units were granted on July 8, 2025. Beginning on July 8, 2026, the shares underlying the restricted stock units will vest in three equal annual installments.